Takeda Pharmaceuticals USA Inc.

01/16/2024 | Press release | Distributed by Public on 01/16/2024 07:03

U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.